UK markets close in 8 hours 11 minutes
  • FTSE 100

    6,957.02
    +53.11 (+0.77%)
     
  • FTSE 250

    23,543.05
    +141.33 (+0.60%)
     
  • AIM

    1,258.92
    +3.92 (+0.31%)
     
  • GBP/EUR

    1.1658
    +0.0023 (+0.19%)
     
  • GBP/USD

    1.3674
    +0.0015 (+0.11%)
     
  • BTC-GBP

    31,382.72
    -2,153.29 (-6.42%)
     
  • CMC Crypto 200

    1,074.62
    -59.76 (-5.27%)
     
  • S&P 500

    4,357.73
    -75.26 (-1.70%)
     
  • DOW

    33,970.47
    -614.41 (-1.78%)
     
  • CRUDE OIL

    71.13
    +0.84 (+1.20%)
     
  • GOLD FUTURES

    1,762.40
    -1.40 (-0.08%)
     
  • NIKKEI 225

    29,839.71
    -660.34 (-2.17%)
     
  • HANG SENG

    24,086.25
    -12.89 (-0.05%)
     
  • DAX

    15,233.45
    +101.39 (+0.67%)
     
  • CAC 40

    6,455.81
    0.00 (0.00%)
     

Novo Nordisk A/S – Share repurchase programme

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 4 August 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.

Under the programme initiated 7 May 2021, Novo Nordisk has repurchased B shares for an amount up to DKK 3.3 billion in the period from 10 May 2021 to 3 August 2021. The programme is now concluded.

Since the announcement as of 26 July 2021, the following transactions have been made:

Number of
B shares

Average
purchase price

Transaction
value, DKK

Accumulated, last announcement

5,656,169

2,903,108,782

26 July 2021

100,000

565.65

56,565,386

27 July 2021

100,000

562.97

56,297,265

28 July 2021

100,000

569.30

56,929,904

29 July 2021

100,000

573.34

57,333,894

30 July 2021

100,000

576.54

57,653,760

2 August 2021

100,000

577.19

57,719,398

3 August 2021

93,468

581.92

54,391,339

Accumulated under the programme

6,349,637

3,299,999,727

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 17,552,912 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 18 billion during a 12-month period beginning 3 February 2021. As of 3 August 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 18,714,414 B shares at an average share price of DKK 474.84 per B share equal to a transaction value of DKK 8,886,358,976.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:

Mette Kruse Danielsen

+45 3079 3883

mkd@novonordisk.com

Michael Bachner (US)

+1 609 664 7308

mzyb@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Ann Søndermølle Rendbæk

+45 3075 2253

arnd@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Mark Joseph Root (US)

+1 848 213 3219

mjhr@novonordisk.com

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting